Business Trends– category –
-
Cell Therapy Weekly: uniQure Plans BLA Submission for Huntington’s Gene Therapy AMT-130; Ernexa Prepares IND for iMSC, Autolus Reports Early Phase I Data for SLE CAR-T
Cell & Gene Therapy Insights USA Overview uniQure plans to submit a Biologics License Application (BLA) for AMT-130, a gene therapy for Huntington's disease, in Q3 2026, based on three-year Phase I/II data. Ernexa Therapeutics has comple... -
Portal Biotechnologies Raises $9M to Expand Cell Engineering Platform, Attracting Merck & Co. and AbbVie
FirstWord HealthTech USA Overview Portal Biotechnologies secured $9 million to advance its cell engineering platform, which has drawn partnerships with Merck & Co. and AbbVie. The platform leverages mechanoporation for efficient intr... -
Cellares Secures $327M in Series D Funding, Including ARK Invest, and Expands Major Manufacturing Agreements with Bristol Myers Squibb and Cabaletta Bio
AllSci USA Overview Cellares has extended its Series D financing to $327 million with a new $50 million investment, specifically aimed at scaling cell therapy manufacturing. As an Integrated Development and Manufacturing Organization (ID... -
Pharmaceutical and Biotech M&A Surges in 2026, Driven by Pipeline Reinforcement and Expansion into Emerging Therapeutic Areas
DistilINFO Publications USA Overview The pharmaceutical and biotechnology sectors are experiencing a significant surge in M&A activity in 2026, as major drugmakers actively seek to fortify their pipelines and expand into novel therap... -
CCRM, OmniaBio, and Avectas Collaborate to Automate and Scale Cell Therapy Manufacturing
PR Newswire Canada Overview CCRM and its CDMO subsidiary OmniaBio Inc. have partnered with Avectas Limited to evaluate and integrate Avectas' automated, scalable cell therapy manufacturing platform. This collaboration aims to enhance con... -
Top Cell Therapy Startups Secure Significant Funding for Commercialization, Infrastructure, and Novel Modalities
New Market Pitch USA Overview Leading cell therapy startups are attracting substantial investment, indicating investor confidence in high-risk technical innovation. Companies like Orca (near-commercial assets), Cellares (manufacturing in... -
iPS-Derived Dopaminergic Neuron Transplants Show Early Safety and Efficacy, Offering New Hope for Parkinson’s Disease Treatment
NeurologyLive USA Overview Stem cell therapy involving the transplantation of iPS cell-derived dopaminergic neurons into the brain is emerging as a promising approach for Parkinson's disease (PD) treatment. Initial clinical trial results... -
Minaris Strengthens Philadelphia GMP Facility, Integrating Cell & Gene Therapy Manufacturing and Testing to Streamline Production
BriefGlance.com USA Overview Minaris, a leading CDMO, has significantly upgraded its GMP cell banking suite at its Philadelphia facility, aiming to streamline cell and gene therapy production. This expansion integrates manufacturing and ... -
Intellia Therapeutics Reports “Paradigm-Shifting” Phase 3 Data for Lonvoguran Ziclumeran, Achieving 87% Reduction in HAE Attacks with Single In Vivo CRISPR Dose
Fierce Biotech USA Overview Intellia Therapeutics announced groundbreaking Phase 3 HAELO trial data for lonvoguran ziclumeran (lonvo-z), an *in vivo* CRISPR gene-editing therapy for hereditary angioedema (HAE). This one-time treatment de... -
Beam Therapeutics Receives FDA IND Clearance for BEAM-304, Advancing Base Editing Therapy for Phenylketonuria (PKU) into Clinical Development
GlobeNewswire USA Overview Beam Therapeutics Inc. announced that the FDA has cleared its Investigational New Drug (IND) application for BEAM-304, a base editing therapy for Phenylketonuria (PKU). PKU is a rare genetic metabolic disorder ...
